Glycobiologists are experts in the field of glycobiology, which focuses on the study of glycans—complex carbohydrates that are fundamental components of all living organisms. Glycans are involved in processes such as inflammation, cell-cell interactions, and the recognition of pathogens, making them essential for understanding both health and disease. Glycobiologists analyze how changes in glycan structures can contribute to the progression of diseases such as cancer, diabetes, and viral infections. Their research uncovers the ways that glycan alterations affect cellular behavior, providing essential insights into disease mechanisms.
In addition to advancing basic scientific understanding, glycobiologists play a key role in the development of innovative therapeutics and diagnostic tools. By identifying specific glycan signatures associated with diseases, these experts contribute to the design of targeted therapies, including personalized medicines and vaccines. Their work has implications in drug discovery, helping to improve the efficacy and safety of treatments. Glycobiologists are driving forward the understanding of the glycan-based biology that underpins many diseases, providing new avenues for treatment. Their expertise is crucial for the continued advancement of medical science and the development of more effective, precision-targeted therapies. As the field of glycobiology continues to grow, their contributions will be pivotal in shaping the future of healthcare.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia